Concern among US consumers about the possible side effects of some fat-free products is driving down the market for fat replacers, says analyst Frost & Sullivan.
Researchers for a new report found that American sales of fat substitutes dipped 1.7% to $399 million in 2000 following negative publicity about Olestra. Clinical tests found that Olestra consumption reduced the absorption of nutrients and caused abdominal symptoms in some subjects.
Manufacturers must actively overcome the problems caused by Olestra’s now poor reputation, said Frost & Sullivan analyst Brad Watkins.
He added: